| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 870 | 2020 |
| The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers E Paplomata, R O’Regan Therapeutic advances in medical oncology 6 (4), 154-166, 2014 | 462 | 2014 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610, 2020 | 321 | 2020 |
| Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer … M Radovich, G Jiang, BA Hancock, C Chitambar, R Nanda, C Falkson, ... JAMA oncology 6 (9), 1410-1415, 2020 | 147 | 2020 |
| Everolimus: side effect profile and management of toxicities in breast cancer E Paplomata, A Zelnak, R O’Regan Breast cancer research and treatment 140, 453-462, 2013 | 88 | 2013 |
| Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final … G Curigliano, V Mueller, V Borges, E Hamilton, S Hurvitz, S Loi, R Murthy, ... Annals of Oncology 33 (3), 321-329, 2022 | 65 | 2022 |
| Impact of tamoxifen therapy on fertility in breast cancer survivors LM Shandley, JB Spencer, A Fothergill, AC Mertens, A Manatunga, ... Fertility and sterility 107 (1), 243-252. e5, 2017 | 55 | 2017 |
| P38 MAPK contributes to resistance and invasiveness of HER2-overexpressing breast cancer SM Donnelly, E Paplomata, BM Peake, E Sanabria, Z Chen, R Nahta Current medicinal chemistry 21 (4), 501-510, 2014 | 54 | 2014 |
| Insulin-like Growth Factor-1 receptor signaling increases the invasive potential of Human Epidermal growth factor Receptor 2–overexpressing breast cancer cells via Src-focal … E Sanabria-Figueroa, SM Donnelly, KC Foy, MC Buss, RC Castellino, ... Molecular Pharmacology 87 (2), 150-161, 2015 | 40 | 2015 |
| New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus E Paplomata, R O’Regan Therapeutics and clinical risk management, 27-36, 2013 | 31 | 2013 |
| Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach? E Paplomata, R Nahta, RM O'Regan Cancer 121 (4), 517-526, 2015 | 28 | 2015 |
| BRE12-158: a postneoadjuvant, randomized phase II trial of personalized therapy versus treatment of physician's choice for patients with residual triple-negative breast cancer BP Schneider, G Jiang, TJ Ballinger, F Shen, C Chitambar, R Nanda, ... Journal of Clinical Oncology 40 (4), 345-355, 2022 | 20 | 2022 |
| Signet ring cell carcinoma of the ampulla of Vater with leptomeningeal metastases: a case report E Paplomata, L Wilfong Journal of Clinical Oncology 29 (21), e627-e629, 2011 | 20 | 2011 |
| Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain … NU Lin, RK Murthy, V Abramson, C Anders, T Bachelot, PL Bedard, ... JAMA oncology 9 (2), 197-205, 2023 | 16 | 2023 |
| Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases … NU Lin, RK Murthy, V Abramson, C Anders, T Bachelot, P Bedard, ... CANCER RESEARCH 82 (4), 2022 | 12 | 2022 |
| Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases … G Curigliano, V Mueller, VF Borges, EP Hamilton, SA Hurvitz, S Loi, ... Journal of Clinical Oncology 39 (15_suppl), 1043-1043, 2021 | 11 | 2021 |
| Predictors of survival after yttrium-90 radioembolization of chemotherapy-refractory hepatic metastases from breast cancer NA Davisson, ZL Bercu, SC Friend, E Paplomata, RM Ermentrout, ... Journal of Vascular and Interventional Radiology 31 (6), 925-933, 2020 | 11 | 2020 |
| Abstract GS5-02: Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative … M Radovich, G Jiang, C Chitambar, R Nanda, C Falkson, FC Lynce, ... Cancer Research 80 (4_Supplement), GS5-02-GS5-02, 2020 | 11 | 2020 |
| Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to … V Mueller, A Wardley, E Paplomata, E Hamilton, A Zelnak, ... European Journal of Cancer 153, 223-233, 2021 | 9 | 2021 |
| Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases … R Murthy, S Loi, A Okines, E Paplomata, E Hamilton, S Hurvitz, N Lin, ... Cancer research 80 (Suppl. 4), 2020 | 9 | 2020 |
